Literature DB >> 6573947

Cytogenetic characterization of ten cases of Ph1-positive acute myelogenous leukemia.

M Sasaki, K Kondo, T Tomiyasu.   

Abstract

Chromosome banding analyses were made on 10 cases of Ph1-positive AML (7 M1 and 3 M2). The standard type Ph1 translocation, t(9q +;22q -), was identified in all of them. Karyotypically normal cells were observed in 6-65% of bone marrow metaphases at the initial cytogenetic examination of 7 patients, whereas the remaining 3 patients had only Ph1-positive cells at diagnosis. Follow-up studies performed in 5 cases indicated that the frequency of karyotypically normal cells increased up to 81-100% when the patients were in remission, whereas it was much reduced in relapse. In 5 cases, there was observed a clone of cells in which the Ph1 translocation was the sole karyotypic abnormality. Various types of other chromosome abnormalities, in addition to the Ph1, were observed in all cases, among which-7 was the most frequent, being found in three cases as a stem line. Other additional changes encountered were + Ph1, del(5), i(17q), - 10, + 18, + X, and various numerical and structural changes including certain secondary translocations that occurred in the Ph1 (22q -) or its partner (9q +). The types and frequencies of these additional changes appeared to be different from those found in the acute phase of CML or in Ph1-positive ALL.

Entities:  

Mesh:

Year:  1983        PMID: 6573947     DOI: 10.1016/0165-4608(83)90032-8

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  2 in total

Review 1.  Chromosome abnormalities in acute leukemia: its clinical implications and age of onset.

Authors:  R Abe; Y Shiga; T Uchida; S Kariyone
Journal:  Indian J Pediatr       Date:  1989 Nov-Dec       Impact factor: 1.967

2.  Transposition of c-abl oncogene in a case of masked Ph chromosome duplicated in blastic phase.

Authors:  E Maserati; P Cavalli; R Casalone; S Morandi; F Pasquali
Journal:  Hum Genet       Date:  1988-03       Impact factor: 4.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.